LLY · News · 20260806N

Foghorn Collaboration Revenue

ELI LILLY & Co · 2026-08-06 · Importance 56 · Surprise 82

Foghorn Therapeutics reported that a $14.2 million cumulative catch-up adjustment from its Eli Lilly collaboration materially increased Q2 2026 collaboration revenue. Foghorn’s revenue rose to $16.1 million from $7.6 million year over year, while its net loss narrowed to $7.2 million from $17.9 million. The collaboration indicates continued financial and development activity under Lilly’s partnership with Foghorn, although Foghorn stated that additional financing will be needed for ongoing development.

Key facts

• Foghorn's revenue rose to $16.1 million in Q2 2026 from $7.6 million year-over-year. source
• Foghorn's net loss decreased to $7.2 million in Q2 2026 from $17.9 million year-over-year. source
• Foghorn received a $14.2 million cumulative catch-up adjustment from its Eli Lilly collaboration in Q2 2026. source
• Foghorn had $167.6 million in cash and marketable securities, which the company said is expected to fund operations for at least 12 months. source
• Foghorn reported Q2 2026 collaboration revenue of $16.1 million. source